Page last updated: 2024-12-05

isophthalate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isophthalate is a chemical compound derived from isophthalic acid. It is a benzene dicarboxylate with the formula C6H4(CO2)2. Isophthalate salts and esters are used in various applications, including plastics, resins, and polymers. The synthesis of isophthalates typically involves the esterification of isophthalic acid with alcohols. Isophthalates are known for their high thermal stability, good electrical insulation properties, and resistance to hydrolysis. They are used in the production of polyester resins, which are used in fiberglass-reinforced plastics, automotive parts, and construction materials. Isophthalates have also been studied for their potential applications in various fields, such as pharmaceuticals, cosmetics, and electronics. The research on isophthalates focuses on their properties, synthesis methods, and applications.'

isophthalate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isophthalic acid : A benzenedicarboxylic acid that is benzene substituted by carboxy groups at position 1 and 3. One of three possible isomers of benzenedicarboxylic acid, the others being phthalic and terephthalic acids. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5461079
CHEBI ID30803
MeSH IDM0166180
PubMed CID8496
CHEMBL ID1871181
CHEBI ID30802
SCHEMBL ID22462
MeSH IDM0166180

Synonyms (91)

Synonym
acide isophtalique [french]
kyselina isoftalova [czech]
wln: qvr cvq
nsc15310
1,3-benzenedicarboxylate
CHEBI:30803
benzene-1,3-dicarboxylate
isophthalate
isophthalate(2-)
I19209_ALDRICH ,
NCGC00164010-01 ,
pb256786246
aids018124
aids-018124
55185-18-7
smr000112097
mls001075180 ,
m-benzene-1,3-dicarboxylic acid
QQVIHTHCMHWDBS-UHFFFAOYSA-L
Q27113988
brn 1909332
einecs 204-506-4
ai3-16107
nsc 15310
hsdb 2090
inchi=1/c8h6o4/c9-7(10)5-2-1-3-6(4-5)8(11)12/h1-4h,(h,9,10)(h,11,12
benzene-1,3-dicarboxylic acid
acide isophtalique
nsc-15310
1,3-benzenedicarboxylic acid
121-91-5
m-benzenedicarboxylic acid
isophthalic acid
m-phthalic acid
kyselina isoftalova
meta-benzenedicarboxylic acid
CHEBI:30802 ,
isophthalic acid, 99%
4-09-00-03292 (beilstein handbook reference)
FT-0693429
I0155
AKOS000119766
A23846
NCGC00164010-02
NCGC00164010-03
ccris 8899
ec 204-506-4
x35216h9fj ,
unii-x35216h9fj
cas-121-91-5
tox21_300106
NCGC00254219-01
tox21_200409
NCGC00257963-01
dtxcid301485
dtxsid3021485 ,
STL163327
BBL011591
HMS2269O09
CHEMBL1871181
FT-0627450
isophthalic acid [inci]
3-carboxybenzoic acid
m-dicarboxybenzene
isophthalic acid [mi]
isoterephthalic acid
m-carboxybenzoic acid
isophthalic acid [hsdb]
BP-21126
SCHEMBL22462
iso-phthalic acid
benzene-1,3-dioic acid
isopthalic acid
benzene,1,3-dicarboxylic acid
3-carboxybenzoic acid; isoterephthalic acid; nsc 15310; m-benzenedicarboxylic acid
J-521560
J-004707
mfcd00002516
isophthalic acid, analytical standard
DS-6425
Q415253
8g0 ,
EN300-19753
AMY30288
1,3-dicarboxybenzene
CS-0020265
C22203
isophthalic acid pound pia)
26776-13-6
1,3-benzene dicarboxylic acid
Z104475158

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Of the isomers examined, PA appeared to be the most toxic and may serve as a surrogate biomarker for reproductive toxicity following mixed exposure to phthalates."( Comparative Cytotoxicity and Sperm Motility Using a Computer-Aided Sperm Analysis System (CASA) for Isomers of Phthalic Acid, a Common Final Metabolite of Phthalates.
Kwack, SJ; Lee, BM, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" More importantly, these macrocyclic inhibitors also displayed in vivo amyloid lowering when dosed in a murine model."( Macrocyclic inhibitors of beta-secretase: functional activity in an animal model.
Allison, T; Coburn, CA; Crouthamel, M; Ellis, J; Espeseth, AS; Graham, SL; Hazuda, D; Holloway, MK; Huang, Q; Jin, L; Lineberger, J; Munshi, S; Pietrak, BL; Price, EA; Sankaranarayanan, S; Simon, AJ; Stachel, SJ; Vacca, JP; Wu, G, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
dicarboxylic acid dianionA carboxylic acid dianion obtained by deprotonation of both carboxy groups of any dicarboxylic acid.
benzenedicarboxylic acidA member of the class of benzoic acids in that consists of benzene substituted by two carboxy groups (A closed class).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
L-glutamate degradation IX (via 4-aminobutanoate)234
5,5'-dehydrodivanillate degradation516

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency2.77510.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency15.84890.000221.22318,912.5098AID588516
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency48.12760.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency12.79030.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.19490.000229.305416,493.5996AID743075
TAR DNA-binding protein 43Homo sapiens (human)Potency3.54811.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID631928Ratio of caffeic acid IC50 to compound IC50 for antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhagic lesion formation compound incubated with venom for 10 mins and administered subcutaneously2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID631930Dissociation constant, pKa of the compound2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID631927Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhagic lesion formation compound incubated with venom for 10 mins and administered subcutaneously measured after 24 hrs2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID631929Ratio of benzoic acid IC50 to compound IC50 for antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhagic lesion formation compound incubated with venom for 10 mins and administered subcutaneously2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (111)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (4.50)18.7374
1990's7 (6.31)18.2507
2000's32 (28.83)29.6817
2010's55 (49.55)24.3611
2020's12 (10.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.96 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index58.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (0.93%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other106 (99.07%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]